In a phase I/II study (NCT03634982) with RMC-4630, including patients with tumors harboring RAS alterations (including KRAS amplification), initial clinical data showed a disease control rate of 71% (5/7 patients) with tumor volume reduction observed in three patients (43%) and a confirmed objective response in one patient with KRASG12C-mutated lung cancer [61]. Here, KRAS is linked to neoplasm.